Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 9
2013 8
2014 1
2015 4
2016 4
2017 8
2018 10
2019 13
2020 8
2021 20
2022 18
2023 24
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.
Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R. Shelan M, et al. Among authors: mohamad o. Prostate Cancer Prostatic Dis. 2024 Apr 8. doi: 10.1038/s41391-024-00829-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38589645 Free article. Review.
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
Roy S, Saad F, Malone S, Agarwal N, Mohamad O, Morgan SC, Malone J, Swami U, Jia AY, Gebrael G, Mendiratta P, Brown JR, Rao SK, Sun Y, Wallis CJD, Chi KN, Chowdhury S, Kishan AU, Spratt DE. Roy S, et al. Among authors: mohamad o. Eur Urol. 2024 Apr;85(4):398-400. doi: 10.1016/j.eururo.2024.01.003. Eur Urol. 2024. PMID: 38485300 No abstract available.
Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.
Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Spratt DE, et al. Among authors: mohamad o. NEJM Evid. 2023 Aug;2(8):EVIDoa2300023. doi: 10.1056/EVIDoa2300023. Epub 2023 Jun 29. NEJM Evid. 2023. PMID: 38320143
Effects of Wildfire Events on California Radiation Oncology Clinics and Patients.
Lichter KE, Baniel CC, Do I, Medhat Y, Avula V, Nogueira LM, Bates JE, Paulsson A, Malik N, Hiatt RA, Yom SS, Mohamad O. Lichter KE, et al. Among authors: mohamad o. Adv Radiat Oncol. 2023 Oct 22;9(3):101395. doi: 10.1016/j.adro.2023.101395. eCollection 2024 Mar. Adv Radiat Oncol. 2023. PMID: 38304108 Free PMC article.
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. Ross AE, et al. Among authors: mohamad o. Eur Urol Oncol. 2024 Jan 31:S2588-9311(24)00029-4. doi: 10.1016/j.euo.2024.01.004. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38302323
122 results